GlassScriptPhysician profile
Luke Peter Legakis
NPI 1316566250
$14,689.12
in general payments reported to CMS, 2019-2025
15 companies · $2,444 in 2025
The $2,444 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $81.97 · 2024: $12K · 2025: $2,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $12K · Education: $1,616 · Food and Beverage: $1,273 · Consulting Fee: $37.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $11,762.93 |
| Education | $1,616.00 |
| Food and Beverage | $1,272.71 |
| Consulting Fee | $37.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| F. Hoffmann-La Roche Ag | $12,163.33 | 2024 | |
| Jubilant Hollisterstier LLC | $1,616.00 | 2025 | |
| Csl Behring | $222.88 | 2025 | Andembry, Hizentra |
| Amgen INC. | $148.31 | 2025 | Actimmune |
| Regeneron Healthcare Solutions, INC. | $71.11 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $67.53 | 2025 | Tezspire, Airsupra |
| Genzyme Corporation | $64.50 | 2025 | |
| Novartis Pharmaceuticals Corporation | $63.39 | 2025 | |
| Biocryst US Sales Co., LLC | $49.06 | 2023 | Orladeyo |
| Glaxosmithkline, LLC. | $47.65 | 2025 | Nucala |
| Ars Pharmaceuticals Operations, INC. | $44.56 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $37.48 | 2025 | |
| Pharming Healthcare, INC. | $36.83 | 2025 | Ruconest |
| Dermavant Sciences, INC. | $32.91 | 2023 | Vtama |
| Genentech USA, INC. | $23.58 | 2025 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Legakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.